By Sophie Lindqvist

Aspen has secured approval to produce generic versions of Ozempic and Wegovy, and expects to start selling them in Canada, Brazil and South Africa within months. The decision puts the South African pharmaceutical group directly into a global race among drugmakers to launch lower-cost copies of semaglutide, the active ingredient behind Novo Nordisk's diabetes and weight-loss blockbusters.

The commercial logic is straightforward. Semaglutide (a GLP-1 receptor agonist, a drug class that mimics a gut hormone to regulate blood sugar and appetite) has lost patent protection in key jurisdictions. That expiry has opened the door for generics manufacturers to undercut Novo Nordisk's pricing in markets where the originals remain out of reach for most patients.

Aspen said it is betting on the generic versions to drive growth in emerging markets and selected international markets. The company did not specify launch dates, pricing, or expected volumes — a gap worth noting, because regulatory clearance and profitable commercialisation are two different things.

How big is the market Aspen is chasing?

In South Africa alone, sales of GLP-1 medicines have grown to nearly R3bn, according to Aspen's own figures. Eli Lilly's Mounjaro accounts for more than half of that market. The number signals strong demand for obesity and diabetes treatments — but it also shows whose lunch Aspen is trying to eat, and it is not only Novo Nordisk's.

That figure deserves a caveat: it comes from Aspen itself, a party with an obvious interest in portraying the market as large and fast-growing. Independent verification of the R3bn number is not offered in the company's statement.

What does this change for Eli Lilly?

Potentially a great deal, and here the story becomes more complicated than a simple Novo-versus-generics narrative. Aspen is Eli Lilly's distributor for Mounjaro in sub-Saharan Africa. The same company that distributes Lilly's branded product will now compete in the same therapeutic class with cheaper semaglutide copies.

Aspen has not said how it intends to manage that conflict — whether it will prioritise the higher-margin distribution arrangement or push its own generic. Lilly, for its part, has not commented on the arrangement in the material made public. The dual role is legal; whether it is comfortable for both partners is a question the company's statements leave unanswered.

Who makes the drug?

Not Aspen, at least not the molecule itself. The company is sourcing the active pharmaceutical ingredient (the biologically active component of a medicine) from third-party suppliers, including India's Dr. Reddy's Laboratories for the Canadian market.

That detail matters for two reasons. First, it means Aspen's margin depends on supplier terms it does not control. Second, supply chains for semaglutide have been under strain globally; reliance on third-party API producers exposes the launch timeline to bottlenecks the company cannot independently fix.

What is not said

The announcement names three launch markets and a vague window of "the coming months." It does not disclose:

• launch pricing in any market
• expected revenue or volume targets
• which suppliers will serve Brazil and South Africa
• whether additional regulatory approvals are still pending

Each omission is standard for a first-mover announcement, and each will determine whether this becomes a genuine growth driver or a footnote. Generic drugmakers routinely win approvals and then struggle on price erosion and distribution.

The strategic read

For Aspen, the move fits a pattern: take proven molecules, strip out the originator's premium, and sell at scale in markets where price sensitivity is high and branded supply is thin. Canada, Brazil and South Africa all fit that profile.

The stakes are real. Novo Nordisk's semaglutide franchise generates tens of billions of dollars annually, and even a small share of demand redirected to generics in price-sensitive markets would be material for a mid-sized player like Aspen. Whether Aspen can capture that share depends on execution details it has not yet disclosed — pricing, supply security, and the awkward question of how hard it is willing to compete against a product it also distributes.